|
Market Cap (1-Jul) $6,688,688 (1,207th) |
Close (30-Jun) $0.200 |
Volume (30-Jun) 1,808,064 |
Shortsold (12-Jun) 8,499 (0.01%) (521st) |
|
52w High $0.100 |
52w Low $0.059 |
P/E - |
EPS 0 |
IXC released this announcement to the ASX on 6 July 2022, 9:57. The announcement is marked as price sensitive, and is 11 page(s) in length and 454.29kb in size.
You can view all announcements from IXC and see how they appear on a price chart on the announcements page.
At the date of this announcement, IXC was 0.023% short sold according to ASIC data. It was ranked the 554th most shorted stock on the ASX. It is now ranked as the 521st most shorted stock on the ASX with 0.011% of total shares short sold as of the latest reported data (12 June 2025).
| Other Recent Announcements from IXC | |
|---|---|
| Phase III Clinical Trial Update and New IIH Market Analysis | 28 June 2023, 8:40 |
| Invex Granted European Orphan Drug Designation for TBI | 23 June 2023, 8:18 |
| Invex Receives Regulatory Approval for IIH EVOLVE in France | 21 April 2023, 8:17 |
| Quarterly Activities/Appendix 4C Cash Flow Report | 6 July 2022, 9:57 |
| HREC and TGA Approval to Commence Phase 3 in Australia | 4 July 2022, 8:46 |
| Appendix 4C and Investor Conference Call Details | 1 July 2022, 11:04 |
| Invex Receives UK Approval to Commence Phase III Trial | 29 June 2022, 8:29 |
You must be logged in to post a reply.
Invex Therapeutics Ltd 